To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Platelet-rich plasma improves WOMAC scores compared to hyaluronic acid in knee OA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
July 2016

Platelet-rich plasma improves WOMAC scores compared to hyaluronic acid in knee OA

Vol: 5| Issue: 7| Number:53| ISSN#: 2564-2537
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A

Efficacy of Platelet-Rich Plasma versus Hyaluronic Acid for treatment of Knee Osteoarthritis: A systematic review and meta-analysis.

Electron Physician. 2016 Mar 25;8(3):2115-22. doi: 10.19082/2115. eCollection 2016.

Contributing Authors:
HN Sadabad M Behzadifar F Arasteh HR Dehghan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

6 randomized clinical trials were included in this meta-analysis to evaluate the comparative efficacy of platelet-rich plasma (PRP) and hyaluronic acid (HA) in the management of knee osteoarthritis. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to evaluate outcome. The results of this meta-analysis demonstrated low-quality evidence that PRP provided favourable...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue